For a drug that is practically insoluble in water and sparingly soluble in ethanol and DMSO, how may each of the following factors be manipulated to maximize the drug exposure when applied into a sustained-release injection (parenteral or IV) formulation?

  • particle size distribution
  • API crystal form (anhydrous/monohydrate) -> any effect?
  • suspension solution (aqueous/oil)
  • route of administration (SC/IV/IM)
  • metabolizing enzyme induction/inhibition (CYP/UGT)

Similar questions and discussions